Cleveland Clinic

Experts on spasticity provide advice for practicing clinicians to optimize patient outcomes.

The director of the Cleveland Lou Ruvo Center for Brain Health at Cleveland Clinic discussed new diagnostic techniques that show promise for advancing the understanding of brain pathologies like Alzheimer and Lewy Body diseases. [WATCH TIME: 3 minutes]

The director of the Cleveland Lou Ruvo Center for Brain Health at Cleveland Clinic talked about challenges of accurately diagnosing dementia with Lewy bodies as well as new methods that show promise in guiding treatment. [WATCH TIME: 3 minutes]

Experts on spasticity explore real-world outcomes and treatment trends in the disease treatment landscape.

Experts on spasticity discuss the potential use of ITB pumps earlier in therapy to optimize patient outcomes.

Experts on spasticity outline the practical considerations in using ITB therapy, including access, risks, and pump malfunctions.

Experts on spasticity discuss how patients do with ITB over the long term, highlighting replacement and discontinuation data from the Product Surveillance Registry.

Patricia Clark, CNP, a nurse practitioner at the Cleveland Clinic, talked about a specialized program for hospitalized patients with Parkinson disease that aligns hospital protocols with home medication regimens to improve care.

The nurse practitioner at the Cleveland Clinic talked about findings from a recent study focused on enhancing medication management and education for patients with Parkinson disease. [WATCH TIME: 5 minutes]

The Cleveland Clinic Foundation Parkinson's Inpatient Program is a proactive, multidisciplinary intervention aimed to enhance the quality and safety of care for hospitalized patients with Parkinson disease.

The nurse practitioner at the Cleveland Clinic talked about a specialized program involving nurse practitioners that aims to improve inpatient care quality and safety for patients with Parkinson disease. [WATCH TIME: 5 minutes]

Glioblastoma, a highly aggressive brain cancer, presents substantial treatment challenges necessitating innovative therapies and interdisciplinary research to improve patient outcomes.

Mark Bain, MD, a neurosurgeon at Cleveland Clinic’s Cerebrovascular Center, provided commentary on the ENRICH trial, a positive study of minimally invasive removal of intracerebral hemorrhage.

The director of the Multiple Sclerosis Program at the Cleveland Clinic’s Lou Ruvo Center for Brain Health discussed findings from a study that compared cognitive profiles between patients with multiple sclerosis and Alzheimer disease. [WATCH TIME: 5 minutes]

The staff neurologist at the Mellen Center for Multiple Sclerosis at Cleveland Clinic talked about findings from a real-world study assessing novel monoclonal antibodies in patients with NMOSD presented at ACTRIMS Forum 2024. [WATCH TIME: 4 minutes]

The director of the Multiple Sclerosis Program at the Cleveland Clinic’s Lou Ruvo Center for Brain Health talked about findings on a study comparing cognitive profiles in older patients with multiple sclerosis vs Alzheimer disease. [WATCH TIME: 5 minutes]

The staff neurologist at the Mellen Center for Multiple Sclerosis at Cleveland Clinic talked about findings from an interim analysis of the phase 2 CALLIPER trial assessing vidofludimus calcium in progressive multiple sclerosis. [WATCH TIME: 4 minutes]

The director of Cleveland Clinic’s Mellen Center for Multiple Sclerosis Treatment and Research talked about recent findings on long-term impact of ozanimod in patients with relapsing-remitting multiple sclerosis presented at ACTRIMS Forum 2024. [WATCH TIME: 4 minutes]

Caroline Just, MD, reflects on the challenges of diagnosing and treating rare neurological diseases, urging for improved education, collaboration, and research efforts.

As part of our monthly clinician spotlight, NeurologyLive® highlighted sleep medicine and epilepsy expert Nancy Foldvary-Schaefer, DO, MS, director of the Sleep Disorders Center and staff in the Epilepsy Center at Cleveland Clinic.

The vascular neurologist and director of the residency program at Cleveland Clinic provided perspective on the biggest learning experiences over the past decade for Cleveland Clinic’s mobile stroke unit. [WATCH TIME: 4 minutes]

The vascular neurologist and director of the residency program at Cleveland Clinic provided perspective on a recently conducted study showing the benefits of timely treatment through mobile stroke units for patients with acute intracerebral hemorrhage. [WATCH TIME: 6 minutes]

The staff neurologist at Cleveland Clinic’s Mellen Center for MS detailed some of the negative impacts issues with access to neurologists and MS care centers can have on patient diagnosis and longterm prognosis. [WATCH TIME: 4 minutes]

The associate professor of neurology at the Cleveland Clinic Learner Institute discussed some of the complexities with genetics in Parkinson disease and the ideas behind developing and administering targeted gene therapies. [WATCH TIME: 4 minutes]

Marisa McGinley, DO, a staff neurologist at Cleveland Clinic’s Mellen Center for MS Treatment and Research, provided forward thoughts on the healthcare reach of neurologists and care access for patients with multiple sclerosis.

The associate professor of neurology at the Cleveland Clinic Lerner Institute provided insight on a recently published meta-analysis identifying independent genome-wide significant loci whose expression is associated with Parkinson disease risk. [WATCH TIME: 5 minutes]

The staff neurologist from the Mellen Center for MS Treatment and Research at the Cleveland Clinic provided perspective on recently published research showing geographic disparities to neurologists and multiple sclerosis centers. [WATCH TIME: 3 minutes]

The neurologist at Cleveland Clinic shared thoughts on a recently published study assessing the relationship between blood biomarkers and change in cognitive function and brain volumes in a cohort of professional fighters.

The assistant professor at Cleveland Clinic discussed findings from a recently published study that provided insights on the understanding of the molecular basis for female predominance in Alzheimer disease. [WATCH TIME: 3 minutes]

While specialists still debate the diagnostics of impaired cognition, the identification of patients at the earliest stages is beginning to be met through new biomarkers and available assays.